Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

The Effects of Exercise Snacks on Endothelial Function and Body Composition in Overweight Individuals

22 kwietnia 2026 zaktualizowane przez: Weifang Medical University
This randomized controlled trial investigates the effects of two types of stair-climbing exercise snacks versus moderate-intensity continuous training on vascular health, body composition, and blood lipids in overweight or obese adults. Participants will be assigned to one of four groups for 6-8 weeks. The control group receives no exercise intervention. Primary outcomes include endothelial function (ultrasound), body composition (InBody), and lipid profile (blood test).

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

This is a parallel group randomized controlled trial, with the study subjects being overweight or obese adults (with a body mass index of ≥ 24 kg/m²). Participants will be recruited from universities and randomly assigned to one of the following four groups:

Short-term stair climbing exercise group Participants climbed the stairs 4 to 5 times a day, each time ascending 5 floors (approximately 1 minute each time). There was at least a 1-hour interval between each exercise session, and the exercises were carried out during daily activities. They exercised 3 to 5 times a week for 6 to 8 weeks.

Long-term stair climbing nutrition supplementation group The participants also conducted 4 to 5 stair climbing training sessions every day. Each training session consisted of 3 sets of climbing 5 floors (the total climbing height for each training session was 15 floors), with a rest period of no more than 1 minute between each set. The interval between two training sessions was no less than 1 hour. They exercised 3 to 5 times a week for 6 to 8 weeks.

Moderate-intensity continuous training group (MICT) Participants engaged in 30-minute moderate-intensity running (including warm-up and cool-down activities) each time, 3 to 5 times a week, for 6 to 8 weeks.

Control group Participants maintained their daily activities and did not receive any exercise intervention measures.

Result measurement indicators:

Vascular health: Assessing endothelial function through ultrasound measurement of flow-mediated vascular dilation (FMD).

Body composition: Measured using the InBody body bioelectrical impedance analyzer (including muscle mass, fat mass and body fat percentage).

Blood lipid test: Collect fasting blood samples and measure low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and total cholesterol (TC).

Measurement time points: Measurements were conducted at the baseline (at the beginning of the study), 3-4 weeks (during the intervention period), and 8 weeks (after the intervention ended).

This research protocol has been approved by the Institutional Review Board of Shandong Second Medical University. All participants are required to sign a written informed consent form.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

60

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  1. Age: 18-35 years old (male, female);
  2. Clear consciousness, stable vital signs;
  3. Able to understand and follow simple instructions;
  4. No regular exercise for at least 3 months;
  5. BMI ≥ 24 kg/m2.

Exclusion Criteria:

  1. There are other serious diseases, such as tumors;
  2. There are other neurological diseases;
  3. There are serious diseases that simultaneously affect the heart, liver, kidneys, endocrine system or hematopoietic system;
  4. There is a history of alcohol or drug abuse;
  5. Participated in other clinical trials that might affect the results of this study;
  6. There are other neurological or musculoskeletal diseases, with pain worsening with exercise;
  7. It is forbidden to engage in physical training.
  8. Within the past 3 months, there have been acute cardiovascular events such as acute myocardial infarction,unstable angina pectoris, severe arrhythmia, acute heart failure, etc.；
  9. Uncontrolled hypertension；
  10. Severe pulmonary diseases, such as uncontrolled asthma, acute exacerbation of chronic obstructive pulmonary disease, interstitial lung disease with significant exercise limitation；
  11. Severe joint and bone diseases, acute soft tissue injuries, fractures that have not healed, etc., making it impossible to complete the prescribed exercise load；
  12. Presence of bleeding tendencies, coagulation dysfunction, or within the past 1 month, there has been major bleeding or a history of surgery；
  13. The investigator judges that there are any other situations that may affect the safety of the subjects or the results of the trial.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Short-term stair climbing exercise snack group
Participants perform short climbs of the stairs 4 to 5 times a day. Each climb involves going up 5 floors (approximately 1 minute), and there is a minimum interval of at least 1 hour between each climb.
Behawioralne: Short-term stair climbing exercise snack group
Adopt a fragmented approach, climbing stairs 4-5 times a day, each time climbing 5 floors (approximately 1 minute per session), with at least 1 hour of interval between each session, and spread throughout the daily activity periods. Exercise 3-5 days per week for a total of 6-8 weeks.
Eksperymentalny: Long-duration stair climbing exercise snack group
Participants climbed the ladder 4 to 5 times a day. Each climb consisted of 2 to 3 sets (each set involved climbing 5 floors, with a rest period of no more than 1 minute between sets), and the total number of floors climbed in a single session was 10 or 15.
Behawioralne: Long-duration stair climbing exercise snack group
On the basis of climbing stairs 4 to 5 times a day, increase the single exercise volume: complete 2 or 3 sets of climbing 5 floors of stairs each time (that is, the total number of floors climbed each time is 10 or 15), with no more than 1 minute of rest between sets. The intervals between each exercise should be at least 1 hour. Exercise 3 to 5 days a week, for a total of 6 to 8 weeks of intervention.
Eksperymentalny: Moderate-intensity continuous exercise
The participants engaged in moderate-intensity running training for 3 to 5 days per week, with each session lasting for 30 minutes.
Behawioralne: Moderate-intensity continuous exercise（MICT）
Exercise 3 to 5 days per week for a total of 6 to 8 weeks. Perform 30 minutes of moderate-intensity running training every day.
Brak interwencji: control group
The participants did not undergo any form of exercise intervention and maintained their usual activity patterns.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Flow-mediated dilation (FMD, relative percentage)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Flow-mediated dilation expressed as a percentage of the baseline brachial artery diameter.Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat mass
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat mass measured by bioelectrical impedance analysis (InBody device). Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Time to peak dilation
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Time required to reach maximal dilation after cuff deflation.Unit of Measure: seconds
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal brachial artery diameter
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Baseline diameter of the brachial artery before cuff inflation.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Peak brachial artery diameter
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Maximal diameter of the brachial artery after reactive hyperemia.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Absolute flow-mediated dilation (FMDabs)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Absolute change in diameter, calculated as peak diameter minus basal diameter.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Standardized FMD
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Flow-mediated dilation adjusted for relevant covariates (e.g., shear stress, baseline diameter) according to standard protocols.Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body weight
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body weight measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat percentage
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat percentage measured by bioelectrical impedance analysis (InBody device).Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body mass index (BMI)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body mass index calculated from weight and height measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg/m²
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal metabolic rate (BMR)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal metabolic rate estimated by bioelectrical impedance analysis (InBody device).Unit of Measure: kcal
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Waist circumference
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Waist circumference measured by bioelectrical impedance analysis (InBody device).Unit of Measure: cm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Visceral fat area
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Visceral fat area measured by bioelectrical impedance analysis (InBody device). Unit of Measure: cm²
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Skeletal muscle mass
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Skeletal muscle mass measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Systolic blood pressure (SBP)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Systolic blood pressure measured using an electronic sphygmomanometer.Unit of Measure: mmHg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Serum high-density lipoprotein (HDL) cholesterol concentration
Ramy czasowe: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum HDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
Diastolic blood pressure (DBP)
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Diastolic blood pressure measured using an electronic sphygmomanometer. Unit of Measure: mmHg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Heart rate
Ramy czasowe: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Heart rate measured using an electronic sphygmomanometer.Unit of Measure: bpm (beats per minute)
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Serum low-density lipoprotein (LDL) cholesterol concentration
Ramy czasowe: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum LDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
Serum total cholesterol concentration
Ramy czasowe: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum total cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
HDL/LDL cholesterol ratio
Ramy czasowe: Measured at baseline and post-intervention (after 6-8 weeks).
Ratio of serum HDL cholesterol to LDL cholesterol calculated from fasting blood samples.Unit of Measure: ratio (dimensionless)
Measured at baseline and post-intervention (after 6-8 weeks).
Serum triglyceride concentration
Ramy czasowe: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum triglyceride concentration measured from blood samples.Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Weifang Medical University

Śledczy

  • Główny śledczy: YANXIA WANG, PhD, Weifang Medical University(Renamed Shandong Second Medical University)

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

16 kwietnia 2026

Zakończenie podstawowe (Szacowany)

16 czerwca 2026

Ukończenie studiów (Szacowany)

20 lipca 2026

Daty rejestracji na studia

Pierwszy przesłany

13 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

30 kwietnia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

30 kwietnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

22 kwietnia 2026

Ostatnia weryfikacja

1 kwietnia 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 2026YX160

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj